Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 10—October 2024
Dispatch

Mpox Epidemiology and Vaccine Effectiveness, England, 2023

Hannah CharlesComments to Author , Katie Thorley, Charlie Turner, Kirsty F. Bennet, Nick Andrews, Marta Bertran, Sema Mandal, Gayatri Amirthalingam, Mary E. Ramsay, Hamish Mohammed, and Katy Sinka
Author affiliation: UK Health Security Agency, London, UK

Main Article

Table 2

Characteristics and risk factors for case-patients with mpox confirmed or highly probable according to specimens collected in 2023, England*

Variable No. (%), n = 128†
HIV status
Living with HIV 13 (10)
HIV negative 69 (54)
Taking HIV PrEP‡ 51 (74)
Not taking PrEP‡ 18 (26)
Unknown
 46 (36)
Modified Vaccinia Ankara–Bavarian Nordic vaccination status§
Vaccinated: >2 doses¶ 30 (23)
Vaccinated: 1 dose 20 (16)
Vaccinated: no. doses unknown 2 (2)
Unvaccinated 54 (42)
Unknown
 22 (17)
Childhood smallpox vaccination status
Vaccinated 4 (3)
Unknown
 124 (97)
Hospital admission
Yes 11 (9)
No 117 (91)
Unknown
Reporting attending events involving multiple sex partners
Yes 28 (22)
No 17 (13)
Unknown 83 (65)
Concurrent STI
Yes 24 (19)
No 28 (22)
Unknown 76 (59)

*Patients were median 36 years of age, range 19–70 years, interquartile range 29–24 years. PrEP, preexposure prophylaxis; STI, sexually transmitted infection. †Unless otherwise stated, denominators are 128; denominators for percentage calculations are HIV-negative persons. ‡We do not have information on HIV treatment or outcomes of treatment for these cases. Nevertheless, most people living with HIV in England take antiretroviral therapy and have an undetectable viral load (8). §Estimated date of vaccination was available for 33 out of 52 vaccinated cases, all of whom received the Modified Vaccinia Ankara–Bavarian Nordic vaccine at least2 weeks before infection. ¶Includes 1 person who reported receiving 3 doses.

Main Article

References
  1. UK Health Security Agency. Monkeypox outbreak: technical briefing 8 [cited 2024 Feb 14]. https://www.gov.uk/government/publications/monkeypox-outbreak-technical-briefings/investigation-into-monkeypox-outbreak-in-england-technical-briefing-8
  2. UK Health Security Agency. Mpox (monkeypox) outbreak: epidemiological overview [cited 2024 Feb 14]. https://www.gov.uk/government/publications/monkeypox-outbreak-epidemiological-overview
  3. UK Health Security Agency. Mpox (monkeypox): case definitions [cited 2024 Feb 14]. https://www.gov.uk/guidance/monkeypox-case-definitions
  4. UK Health Security Agency. Reporting to UKHSA: a guide for diagnostic laboratories [cited 2024 Feb 14]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1159953/UKHSA_Laboratory_reporting_guidelines_May_2023.pdf
  5. UK Health Security Agency. Notifiable diseases and causative organisms: how to report [cited 2024 Feb 14]. https://www.gov.uk/guidance/notifiable-diseases-and-causative-organisms-how-to-report
  6. Flannery  B, Andrews  N, Feikin  D, Patel  MK. Commentary: Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 2023;52:19–21. DOIPubMedGoogle Scholar
  7. Bertran  M, Andrews  N, Davison  C, Dugbazah  B, Boateng  J, Lunt  R, et al. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study. Lancet Infect Dis. 2023;23:828–35. DOIPubMedGoogle Scholar
  8. UK Health Security Agency. HIV action plan monitoring and evaluation framework [cited 2024 Apr 25].[REMOVED HYPERLINKB0036ECA5C0100 FIELD] https://www.gov.uk/government/publications/hiv-monitoring-and-evaluation-framework
  9. Chicago Health Alert Network. Potential risk for new mpox cases—provider update: May 9, 2023 [cited 2024 Feb 14]. https://emergency.cdc.gov/han/2023/han00490.asp
  10. Chicago Department of Public Health. Mpox dashboard [cited 2024 Feb 14]. https://www.chicago.gov/city/en/depts/cdph/provdrs/infectious_disease/supp_info/mpox-home/mpox-dashboard.html
  11. Hazra  A, Zucker  J, Bell  E, Flores  J, Gordon  L, Mitjà  O, et al. Mpox in people with past infection or a complete vaccination course: a global case series. Lancet Infect Dis. 2023.
  12. World Health Organization. Multi-country outbreak of mpox: external situation report #31—22 December 2023 [cited 2024 Feb 14]. https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-31---22-december-2023

Main Article

Page created: August 27, 2024
Page updated: August 27, 2024
Page reviewed: August 27, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external